APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neurotrophins

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurotrophins Market Outlook and Growth Opportunities 2026

19 December 2025195 pages

Choose your research edition.

Industry ResearchNeurotrophins Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurotrophins Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Neurotrophins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurotrophins Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurotrophins Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Neurotrophins market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurotrophins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurotrophins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurotrophins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurotrophins market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurotrophins market include FibroGen, GE Healthcare, Merck Serono, PeproTech, Scil Proteins GmbH, Scil Proteins GmbH, Lonza Groups and Johnson＆Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurotrophins market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurotrophins and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurotrophins sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurotrophins market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurotrophins Segment by Company

FibroGen

GE Healthcare

Merck Serono

PeproTech

Scil Proteins GmbH

Scil Proteins GmbH

Lonza Groups

Johnson＆Johnson

Neurotrophins Segment by Type

Dehydroepiandrosterone Sulfate

Brain-Derived Neurotrophic Factor

Nerve Growth Factor

Other

Neurotrophins Segment by Application

Alzheimer'S Disease

Amyotrophic Lateral Sclerosis

Parkinson'S Disease

Other

Neurotrophins Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neurotrophins status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neurotrophins market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurotrophins significant trends, drivers, influence factors in global and regions.

6. To analyze Neurotrophins competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurotrophins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurotrophins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurotrophins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurotrophins market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurotrophins industry.

Chapter 3: Detailed analysis of Neurotrophins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neurotrophins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neurotrophins in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurotrophins Industry Trends Table 2. Neurotrophins Industry Drivers Table 3. Neurotrophins Industry Opportunities and Challenges Table 4. Neurotrophins Industry Restraints Table 5. Global Neurotrophins Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurotrophins Revenue Share by Company (2021-2026) Table 7. Global Neurotrophins Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Neurotrophins Sales Volume Share by Company (2021-2026) Table 9. Global Neurotrophins Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Neurotrophins Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neurotrophins Key Company Manufacturing Base & Headquarters Table 12. Global Neurotrophins Company, Product Type & Application Table 13. Global Neurotrophins Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurotrophins by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Dehydroepiandrosterone Sulfate Table 18. Significant Companies of Brain-Derived Neurotrophic Factor Table 19. Significant Companies of Nerve Growth Factor Table 20. Significant Companies of Other Table 21. Global Neurotrophins Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Neurotrophins Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Neurotrophins Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Neurotrophins Sales Volume Share by Type (2021-2026) Table 25. Global Neurotrophins Sales Volume Share by Type (2027-2032) Table 26. Global Neurotrophins Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neurotrophins Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Neurotrophins Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Neurotrophins Sales Value Share by Type (2021-2026) Table 30. Global Neurotrophins Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Alzheimer'S Disease Table 32. Significant Companies of Amyotrophic Lateral Sclerosis Table 33. Significant Companies of Parkinson'S Disease Table 34. Significant Companies of Other Table 35. Global Neurotrophins Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Neurotrophins Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Neurotrophins Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Neurotrophins Sales Volume Share by Application (2021-2026) Table 39. Global Neurotrophins Sales Volume Share by Application (2027-2032) Table 40. Global Neurotrophins Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Neurotrophins Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Neurotrophins Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Neurotrophins Sales Value Share by Application (2021-2026) Table 44. Global Neurotrophins Sales Value Share by Application (2027-2032) Table 45. Global Neurotrophins Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Neurotrophins Sales by Region (2021-2026) & (K Units) Table 47. Global Neurotrophins Sales Market Share by Region (2021-2026) Table 48. Global Neurotrophins Sales by Region (2027-2032) & (K Units) Table 49. Global Neurotrophins Sales Market Share by Region (2027-2032) Table 50. Global Neurotrophins Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Neurotrophins Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Neurotrophins Sales Value Share by Region (2021-2026) Table 53. Global Neurotrophins Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Neurotrophins Sales Value Share by Region (2027-2032) Table 55. Global Neurotrophins Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Neurotrophins Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Neurotrophins Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Neurotrophins Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Neurotrophins Sales by Country (2021-2026) & (K Units) Table 60. Global Neurotrophins Sales Market Share by Country (2021-2026) Table 61. Global Neurotrophins Sales by Country (2027-2032) & (K Units) Table 62. Global Neurotrophins Sales Market Share by Country (2027-2032) Table 63. Global Neurotrophins Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Neurotrophins Sales Value Market Share by Country (2021-2026) Table 65. Global Neurotrophins Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Neurotrophins Sales Value Market Share by Country (2027-2032) Table 67. FibroGen Company Information Table 68. FibroGen Business Overview Table 69. FibroGen Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. FibroGen Neurotrophins Product Portfolio Table 71. FibroGen Recent Development Table 72. GE Healthcare Company Information Table 73. GE Healthcare Business Overview Table 74. GE Healthcare Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. GE Healthcare Neurotrophins Product Portfolio Table 76. GE Healthcare Recent Development Table 77. Merck Serono Company Information Table 78. Merck Serono Business Overview Table 79. Merck Serono Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Merck Serono Neurotrophins Product Portfolio Table 81. Merck Serono Recent Development Table 82. PeproTech Company Information Table 83. PeproTech Business Overview Table 84. PeproTech Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. PeproTech Neurotrophins Product Portfolio Table 86. PeproTech Recent Development Table 87. Scil Proteins GmbH Company Information Table 88. Scil Proteins GmbH Business Overview Table 89. Scil Proteins GmbH Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Scil Proteins GmbH Neurotrophins Product Portfolio Table 91. Scil Proteins GmbH Recent Development Table 92. Scil Proteins GmbH Company Information Table 93. Scil Proteins GmbH Business Overview Table 94. Scil Proteins GmbH Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Scil Proteins GmbH Neurotrophins Product Portfolio Table 96. Scil Proteins GmbH Recent Development Table 97. Lonza Groups Company Information Table 98. Lonza Groups Business Overview Table 99. Lonza Groups Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Lonza Groups Neurotrophins Product Portfolio Table 101. Lonza Groups Recent Development Table 102. Johnson＆Johnson Company Information Table 103. Johnson＆Johnson Business Overview Table 104. Johnson＆Johnson Neurotrophins Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Johnson＆Johnson Neurotrophins Product Portfolio Table 106. Johnson＆Johnson Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Neurotrophins Distributors List Table 110. Neurotrophins Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Neurotrophins Product Image Figure 2. Global Neurotrophins Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurotrophins Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neurotrophins Sales (2021-2032) & (K Units) Figure 5. Global Neurotrophins Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Neurotrophins Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Dehydroepiandrosterone Sulfate Image Figure 10. Brain-Derived Neurotrophic Factor Image Figure 11. Nerve Growth Factor Image Figure 12. Other Image Figure 13. Global Neurotrophins Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Neurotrophins Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Neurotrophins Sales Volume Share by Type (2021-2032) Figure 16. Global Neurotrophins Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neurotrophins Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neurotrophins Sales Value Share by Type (2021-2032) Figure 19. Alzheimer'S Disease Image Figure 20. Amyotrophic Lateral Sclerosis Image Figure 21. Parkinson'S Disease Image Figure 22. Other Image Figure 23. Global Neurotrophins Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Neurotrophins Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Neurotrophins Sales Volume Share by Application (2021-2032) Figure 26. Global Neurotrophins Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Neurotrophins Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Neurotrophins Sales Value Share by Application (2021-2032) Figure 29. Global Neurotrophins Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Neurotrophins Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Neurotrophins Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Neurotrophins Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Neurotrophins Sales Value (2021-2032) & (US$ Million) Figure 34. North America Neurotrophins Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Neurotrophins Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Neurotrophins Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Neurotrophins Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Neurotrophins Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Neurotrophins Sales Value (2021-2032) & (US$ Million) Figure 40. South America Neurotrophins Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Neurotrophins Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Neurotrophins Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Neurotrophins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Neurotrophins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Neurotrophins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Neurotrophins Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Neurotrophins Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Dehydroepiandrosterone Sulfate
  • Brain-Derived Neurotrophic Factor
  • Nerve Growth Factor
  • Other
Applications
  • Alzheimer'S Disease
  • Amyotrophic Lateral Sclerosis
  • Parkinson'S Disease
  • Other
Companies covered
  • FibroGen
  • GE Healthcare
  • Merck Serono
  • PeproTech
  • Scil Proteins GmbH
  • Scil Proteins GmbH
  • Lonza Groups
  • Johnson＆Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurotrophins Sales Value (2021-2032)
  4. 1.2.2 Global Neurotrophins Sales Volume (2021-2032)
  5. 1.2.3 Global Neurotrophins Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neurotrophins Market Dynamics
  1. 2.1 Neurotrophins Industry Trends
  2. 2.2 Neurotrophins Industry Drivers
  3. 2.3 Neurotrophins Industry Opportunities and Challenges
  4. 2.4 Neurotrophins Industry Restraints
3 Neurotrophins Market by Company
  1. 3.1 Global Neurotrophins Company Revenue Ranking in 2025
  2. 3.2 Global Neurotrophins Revenue by Company (2021-2026)
  3. 3.3 Global Neurotrophins Sales Volume by Company (2021-2026)
  4. 3.4 Global Neurotrophins Average Price by Company (2021-2026)
  5. 3.5 Global Neurotrophins Company Ranking (2024-2026)
  6. 3.6 Global Neurotrophins Company Manufacturing Base and Headquarters
  7. 3.7 Global Neurotrophins Company Product Type and Application
  8. 3.8 Global Neurotrophins Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neurotrophins Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neurotrophins Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neurotrophins Market by Type
  1. 4.1 Neurotrophins Type Introduction
  2. 4.1.1 Dehydroepiandrosterone Sulfate
  3. 4.1.2 Brain-Derived Neurotrophic Factor
  4. 4.1.3 Nerve Growth Factor
  5. 4.1.4 Other
  6. 4.2 Global Neurotrophins Sales Volume by Type
  7. 4.2.1 Global Neurotrophins Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Neurotrophins Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Neurotrophins Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Neurotrophins Sales Value by Type
  11. 4.3.1 Global Neurotrophins Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Neurotrophins Sales Value by Type (2021-2032)
  13. 4.3.3 Global Neurotrophins Sales Value Share by Type (2021-2032)
5 Neurotrophins Market by Application
  1. 5.1 Neurotrophins Application Introduction
  2. 5.1.1 Alzheimer'S Disease
  3. 5.1.2 Amyotrophic Lateral Sclerosis
  4. 5.1.3 Parkinson'S Disease
  5. 5.1.4 Other
  6. 5.2 Global Neurotrophins Sales Volume by Application
  7. 5.2.1 Global Neurotrophins Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurotrophins Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Neurotrophins Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Neurotrophins Sales Value by Application
  11. 5.3.1 Global Neurotrophins Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neurotrophins Sales Value by Application (2021-2032)
  13. 5.3.3 Global Neurotrophins Sales Value Share by Application (2021-2032)
6 Neurotrophins Regional Sales and Value Analysis
  1. 6.1 Global Neurotrophins Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurotrophins Sales by Region (2021-2032)
  3. 6.2.1 Global Neurotrophins Sales by Region: 2021-2026
  4. 6.2.2 Global Neurotrophins Sales by Region (2027-2032)
  5. 6.3 Global Neurotrophins Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neurotrophins Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neurotrophins Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neurotrophins Sales Value by Region (2027-2032)
  9. 6.5 Global Neurotrophins Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neurotrophins Sales Value (2021-2032)
  12. 6.6.2 North America Neurotrophins Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neurotrophins Sales Value (2021-2032)
  15. 6.7.2 Europe Neurotrophins Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neurotrophins Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neurotrophins Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neurotrophins Sales Value (2021-2032)
  21. 6.9.2 South America Neurotrophins Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neurotrophins Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neurotrophins Sales Value Share by Country, 2025 VS 2032
7 Neurotrophins Country-level Sales and Value Analysis
  1. 7.1 Global Neurotrophins Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurotrophins Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neurotrophins Sales by Country (2021-2032)
  4. 7.3.1 Global Neurotrophins Sales by Country (2021-2026)
  5. 7.3.2 Global Neurotrophins Sales by Country (2027-2032)
  6. 7.4 Global Neurotrophins Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neurotrophins Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neurotrophins Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neurotrophins Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neurotrophins Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neurotrophins Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neurotrophins Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neurotrophins Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neurotrophins Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neurotrophins Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neurotrophins Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neurotrophins Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neurotrophins Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neurotrophins Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neurotrophins Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neurotrophins Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neurotrophins Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neurotrophins Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neurotrophins Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neurotrophins Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neurotrophins Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neurotrophins Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neurotrophins Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neurotrophins Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neurotrophins Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neurotrophins Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neurotrophins Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neurotrophins Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neurotrophins Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neurotrophins Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neurotrophins Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neurotrophins Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neurotrophins Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neurotrophins Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neurotrophins Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neurotrophins Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neurotrophins Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neurotrophins Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neurotrophins Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neurotrophins Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neurotrophins Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neurotrophins Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neurotrophins Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neurotrophins Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neurotrophins Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neurotrophins Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neurotrophins Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neurotrophins Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neurotrophins Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neurotrophins Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neurotrophins Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neurotrophins Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neurotrophins Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neurotrophins Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neurotrophins Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neurotrophins Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neurotrophins Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neurotrophins Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neurotrophins Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neurotrophins Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neurotrophins Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neurotrophins Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neurotrophins Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neurotrophins Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neurotrophins Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neurotrophins Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neurotrophins Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neurotrophins Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neurotrophins Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neurotrophins Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neurotrophins Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neurotrophins Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neurotrophins Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neurotrophins Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neurotrophins Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neurotrophins Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neurotrophins Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neurotrophins Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neurotrophins Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neurotrophins Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neurotrophins Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neurotrophins Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neurotrophins Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neurotrophins Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neurotrophins Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neurotrophins Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neurotrophins Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 FibroGen
  2. 8.1.1 FibroGen Company Information
  3. 8.1.2 FibroGen Business Overview
  4. 8.1.3 FibroGen Neurotrophins Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 FibroGen Neurotrophins Product Portfolio
  6. 8.1.5 FibroGen Recent Developments
  7. 8.2 GE Healthcare
  8. 8.2.1 GE Healthcare Company Information
  9. 8.2.2 GE Healthcare Business Overview
  10. 8.2.3 GE Healthcare Neurotrophins Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GE Healthcare Neurotrophins Product Portfolio
  12. 8.2.5 GE Healthcare Recent Developments
  13. 8.3 Merck Serono
  14. 8.3.1 Merck Serono Company Information
  15. 8.3.2 Merck Serono Business Overview
  16. 8.3.3 Merck Serono Neurotrophins Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Serono Neurotrophins Product Portfolio
  18. 8.3.5 Merck Serono Recent Developments
  19. 8.4 PeproTech
  20. 8.4.1 PeproTech Company Information
  21. 8.4.2 PeproTech Business Overview
  22. 8.4.3 PeproTech Neurotrophins Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 PeproTech Neurotrophins Product Portfolio
  24. 8.4.5 PeproTech Recent Developments
  25. 8.5 Scil Proteins GmbH
  26. 8.5.1 Scil Proteins GmbH Company Information
  27. 8.5.2 Scil Proteins GmbH Business Overview
  28. 8.5.3 Scil Proteins GmbH Neurotrophins Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Scil Proteins GmbH Neurotrophins Product Portfolio
  30. 8.5.5 Scil Proteins GmbH Recent Developments
  31. 8.6 Scil Proteins GmbH
  32. 8.6.1 Scil Proteins GmbH Company Information
  33. 8.6.2 Scil Proteins GmbH Business Overview
  34. 8.6.3 Scil Proteins GmbH Neurotrophins Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Scil Proteins GmbH Neurotrophins Product Portfolio
  36. 8.6.5 Scil Proteins GmbH Recent Developments
  37. 8.7 Lonza Groups
  38. 8.7.1 Lonza Groups Company Information
  39. 8.7.2 Lonza Groups Business Overview
  40. 8.7.3 Lonza Groups Neurotrophins Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lonza Groups Neurotrophins Product Portfolio
  42. 8.7.5 Lonza Groups Recent Developments
  43. 8.8 Johnson＆Johnson
  44. 8.8.1 Johnson＆Johnson Company Information
  45. 8.8.2 Johnson＆Johnson Business Overview
  46. 8.8.3 Johnson＆Johnson Neurotrophins Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Johnson＆Johnson Neurotrophins Product Portfolio
  48. 8.8.5 Johnson＆Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurotrophins Value Chain Analysis
  2. 9.1.1 Neurotrophins Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurotrophins Sales Mode & Process
  6. 9.2 Neurotrophins Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurotrophins Distributors
  9. 9.2.3 Neurotrophins Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst